A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-10-13
Adverse events
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-04-16 (study day 168); relationship: N
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-09 (study day 252); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-16 (study day 290); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-11 (study day 316); relationship: not assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-10-31 (study day 366); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-13 (study day 471); relationship: not assessed
Data queries
No data queries.